TICKERNERD
Menu
VTVTVTVTHealthcare · Biotechnology

VTVT Stock Forecast: vTv Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$34
+1.91% on the day

The 6 Wall Street analysts covering vTv Therapeutics, Inc. hold a median 12-month price target of $56 — +65.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 77 of 100 as at 22 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$131.5M
Ticker Nerd rank
77 / 100
Median analyst target
$56
Analysts covering
6
Revenue$0.0
Operating income−$13.9M
Net income−$13.1M
Free cash flow−$11.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+8.2%
1M
+10.3%
YTD
−15.3%
1Y
+111.8%
From 52W high
−20.7%
From 52W low
+114.6%
$16
$43
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

VTVT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores vTv Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
77 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
95
Quality
85
Volatility
78
Momentum
75
Value
74
Size
73
Revisions
49
Issuance
34
Accruals
11

Growth (95): Sales and profits are climbing, and climbing faster than before.

Accruals (11): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

VTVT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VTVT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50$60$70Oct 25Jan 26Apr 26Jul 26VTVTHigh $67Median $56Low $42

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
6 Buy0 Hold0 Sell
Low $42Median $56High $67

The green dot is the last close — the median target sits +65.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
6 Aug 2026HC Wainwright & Co.MaintainsBuy$45 → $42
16 July 2026BTIGMaintainsBuy$49 → $57
16 July 2026BTIGMaintainsBuy—
12 Mar 2026Evercore ISI GroupInitiatesOutperform—
11 Mar 2026BTIGReiteratesBuy—
27 Jan 2026BTIGMaintainsBuy—
23 Jan 2026Roth CapitalInitiatesBuy—
5 Jan 2026TD CowenInitiatesBuy—
19 Dec 2025HC Wainwright & Co.MaintainsBuy—
19 Nov 2025BTIGInitiatesBuy—
13 Aug 2025HC Wainwright & Co.ReiteratesBuy—
9 Apr 2025HC Wainwright & Co.InitiatesBuy—
9 Dec 2024Alliance Global PartnersInitiatesBuy—
7 Mar 2023HC Wainwright & Co.ReiteratesBuy$6.00
17 Aug 2022Northland Capital MarketsMaintainsOutperform$1.50 → $2.00
18 Feb 2022Cantor FitzgeraldInitiatesOverweight—
10 Feb 2020H.C. WainwrightReiteratesBuy—
10 Feb 2020HC Wainwright & Co.ReiteratesBuy$5.00 → $6.00
30 May 2019H.C. WainwrightInitiatesBuy—
30 May 2019HC Wainwright & Co.InitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VTVT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

VTVT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Aug 2026, vTv Therapeutics, Inc. returned +111.8% against +19.6% for the S&P 500, dividends included.

VTVT vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250Oct 25Jan 26Apr 26Jul 26VTVTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

VTVT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

vTv Therapeutics, Inc. (VTVT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−10.4×

Cheaper than 93% of US stocks

Price / sales
3.6×

Cheaper than 36% of US stocks

Price / book
5.2×

Cheaper than 21% of US stocks

EV / EBITDA
−35.3×

Cheaper than 92% of US stocks

Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−25.1%

Higher than 20% of US stocks

Net margin
−12.9%

Higher than 18% of US stocks

Returns & dividend
Return on equity
−15.8%

Higher than 33% of US stocks

Return on assets
−10.1%

Higher than 26% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

vTv Therapeutics, Inc. (VTVT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • vTv Therapeutics, Inc. has a market value of $131.5M and an enterprise value of $326.5M.

  • Revenue in the twelve months to 30 June 2026: $36.8M. The latest quarter shrank 100.0% year on year.

  • Net income over the same four quarters: −$6.4M, a −17.4% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.06.

  • Free cash flow in the twelve months to 30 June 2026: −$16.8M.

  • Shares outstanding: 3.9M.

  • Trailing P/E: −10.4×; forward P/E: −7.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • vTv Therapeutics, Inc. employs 26 people — $1.4M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 25 Aug 2026

Data provided by Twelve Data

Peers

VTVT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
VTVTvTv Therapeutics, Inc.$131.5M
77
MISTMilestone Pharmaceuticals, Inc.$131.3M
18
CBUSCibus, Inc.$129.5M
34
BDTXBlack Diamond Therapeutics, Inc.$126.6M
55
VANIVivani Medical, Inc.$124.5M
40
ANIXAnixa Biosciences, Inc.$124.4M
84
GUTSFractyl Health, Inc.$123.7M
30

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own vTv Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest VTVT news & analysis

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 19 Aug 2026neutral

vTv Therapeutics announced that it granted 2,500 stock options to purchase shares of common stock to a non-executive employee as a material inducement to employment, in accordance with Nasdaq Listing Rule 5635(c)(4).

Why it matters — This equity grant is a routine corporate action tied to hiring and compensation, providing VTVT watchers with information about the company's employee incentive arrangements.

vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

GlobeNewsWire · 6 Aug 2026positive

vTv Therapeutics reported its second-quarter 2026 financial results and corporate update, stating that enrollment in its Phase 3 CATT1 trial of cadisegliatin for type 1 diabetes is expected to complete in the third quarter of 2026, with a Phase 2a hybrid closed-loop trial to begin before year-end and a Key Opinion Leader event planned for the fourth quarter of 2026. The company said its balance sheet is expected to fund operations through the anticipated CATT1 topline data readout.

Why it matters — The update lays out near-term timelines for key clinical milestones for vTv's lead candidate cadisegliatin and indicates the company expects to be funded through the CATT1 data readout.

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 28 July 2026neutral

vTv Therapeutics granted 23,500 stock options to two non-executive employees as a material inducement to employment, in accordance with Nasdaq Listing Rule 5635(c)(4).

Why it matters — This standard corporate action reflects the company's effort to attract talent as it advances cadisegliatin, a potential first-in-class therapy for type 1 diabetes.

FAQ

Frequently asked questions about VTVT stock

What is the VTVT stock price forecast for 2026-2027?

The 6 Wall Street analysts covering vTv Therapeutics, Inc. have a median 12-month price target of $56, with estimates ranging from $42 to $67. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is VTVT stock a buy right now?

Of the 6 analysts covering vTv Therapeutics, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks vTv Therapeutics, Inc. 77 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank VTVT?

As at 22 Aug 2026, vTv Therapeutics, Inc. ranks 77 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (95 of 100).

Will VTVT stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +65.2% from the last close, and Ticker Nerd's factor model ranks vTv Therapeutics, Inc. 77 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the VTVT stock forecast for 2030?

No analyst covering vTv Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VTVT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $42 to $67 over the next 12 months.

How has VTVT stock performed over the past year?

vTv Therapeutics, Inc. returned +111.8% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does vTv Therapeutics, Inc. do?

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing oral small molecule drug candidates to treat diabetes and other chronic diseases.

What is the latest news on VTVT?

The most recent item we track (GlobeNewsWire, 19 Aug 2026): "vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)". vTv Therapeutics announced that it granted 2,500 stock options to purchase shares of common stock to a non-executive employee as a material inducement to employment, in accordance with Nasdaq Listing Rule 5635(c)(4).

Company

About vTv Therapeutics, Inc.

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing oral small molecule drug candidates to treat diabetes and other chronic diseases. Its lead product candidate, cadisegliatin (TTP399), is an orally administered, liver-selective glucokinase activator in Phase 3 clinical trials as a potential adjunctive therapy to insulin for type 1 diabetes patients. The company advances additional molecules targeting metabolic and inflammatory conditions, including TTP273, an oral glucagon-like peptide 1 receptor agonist for type 2 diabetes; HPP737, a non-central nervous system penetrant phosphodiesterase type 4 inhibitor for inflammatory diseases; and others such as HPP593, Azeliragon, and HPP3033 addressing oxidative stress-related disorders. vTv Therapeutics Inc. maintains license agreements, including with Newsoara Biopharma for phosphodiesterase type 4 inhibitors like HPP737, supporting global development efforts. Founded in 2015 and headquartered in High Point, North Carolina, the company operates in the biotechnology sector, emphasizing innovative oral treatments to address unmet needs in chronic disease management.

CEO Mr. Paul J. Sekhri · 26 employees · United States · https://vtvtherapeutics.com